Suppr超能文献

常规治疗无效的功能性消化不良患者幽门螺杆菌的治疗:一项为期六个月随访的双盲随机试验

Treatment of Helicobacter pylori in functional dyspepsia resistant to conventional management: a double blind randomised trial with a six month follow up.

作者信息

Koelz H R, Arnold R, Stolte M, Fischer M, Blum A L

机构信息

Division of Gastroenterology, Department of Medicine, Triemli Hospital, Zurich, Switzerland.

出版信息

Gut. 2003 Jan;52(1):40-6. doi: 10.1136/gut.52.1.40.

Abstract

BACKGROUND

Previous studies on the treatment of Helicobacter pylori infection in functional dyspepsia have shown little, if any, effect on dyspeptic symptoms. However, whether such treatment might be of benefit in patients resistant to acid inhibitors has not been formally tested.

AIM

The present study investigated the effect of H pylori treatment in patients with functional dyspepsia resistant to conventional treatment.

PATIENTS

A total of 181 H pylori positive patients with chronic functional dyspepsia who had not responded to a one week antacid run-in and two week double blind antisecretory or placebo treatment were included.

METHODS

Patients were randomised to two weeks of treatment with omeprazole 40 mg twice daily combined with amoxicillin 1 g twice daily or omeprazole 20 mg once daily alone. The primary outcome variable ("response") was defined as no need for further therapy or investigations for dyspeptic symptoms 4-6 months after treatment.

RESULTS

H pylori infection was healed in 10% of patients after omeprazole and in 52% after omeprazole plus amoxicillin. The respective "response" rates were 66% and 62% (NS). H pylori treatment and cure of H pylori infection had no effect on complete resolution of all dyspeptic symptoms, individual symptoms, or various aspects of quality of life.

CONCLUSION

In functional dyspepsia, H pylori treatment and cure of H pylori are no more effective for symptoms over six months than short term acid inhibition. These results do not support treatment of H pylori in functional dyspepsia.

摘要

背景

既往关于功能性消化不良患者幽门螺杆菌感染治疗的研究显示,对消化不良症状几乎没有影响(即便有影响也微乎其微)。然而,这种治疗对耐酸抑制剂的患者是否有益尚未经过正式检验。

目的

本研究调查幽门螺杆菌治疗对常规治疗无效的功能性消化不良患者的影响。

患者

纳入了181例幽门螺杆菌阳性的慢性功能性消化不良患者,这些患者对为期1周的抗酸剂导入期治疗以及为期2周的双盲抗分泌或安慰剂治疗均无反应。

方法

患者被随机分为两组,一组接受奥美拉唑40 mg每日2次联合阿莫西林1 g每日2次治疗2周,另一组仅接受奥美拉唑20 mg每日1次治疗。主要结局变量(“反应”)定义为治疗后4 - 6个月无需因消化不良症状进行进一步治疗或检查。

结果

奥美拉唑治疗后10%的患者幽门螺杆菌感染得到治愈,奥美拉唑联合阿莫西林治疗后这一比例为52%。各自的“反应”率分别为66%和62%(无显著差异)。幽门螺杆菌治疗及幽门螺杆菌感染的治愈对所有消化不良症状的完全缓解、个体症状或生活质量的各个方面均无影响。

结论

在功能性消化不良中,幽门螺杆菌治疗及幽门螺杆菌感染的治愈在超过6个月的症状改善方面并不比短期抑酸更有效。这些结果不支持对功能性消化不良患者进行幽门螺杆菌治疗。

相似文献

引用本文的文献

1
ACG and CAG Clinical Guideline: Management of Dyspepsia.ACG 和 CAG 临床指南:消化不良的管理。
Am J Gastroenterol. 2017 Jul;112(7):988-1013. doi: 10.1038/ajg.2017.154. Epub 2017 Jun 20.
7
Drug treatment of functional dyspepsia.功能性消化不良的药物治疗
World J Gastroenterol. 2006 May 7;12(17):2694-700. doi: 10.3748/wjg.v12.i17.2694.

本文引用的文献

4
The management of dyspepsia: a systematic review.消化不良的管理:一项系统综述。
Health Technol Assess. 2000;4(39):iii-v, 1-189. doi: 10.3310/hta4390.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验